Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis

Hepatology

Volumn 59, Issue 5, 2014, Pages 1998-2009

  Mukhopadhyay, Partha ^a   Rajesh, Mohanraj ^a   Cao, Zongxian ^a   Horváth, Béla ^a,b   Park, Ogyi ^a   Wang, Hua ^a   Erdelyi, Katalin ^a   Holovac, Eileen ^a   Wang, Yuping ^a   Liaudet, Lucas ^c   Hamdaoui, Nabila ^d,e   Lafdil, Fouad ^d,e   Haskó, György ^f   Szabo, Csaba ^g   Boulares, A Hamid ^h   Gao, Bin ^a   Pacher, Pal ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d INSERM U955   (France)

^e FACULTÉ DE MÉDECINE   (France)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

^h LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARBON TETRACHLORIDE; HEPATIC STELLATE CELLS; HEPATITIS; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84899494248     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26763     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, et al. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology 2008;48:963-977.
3. Scott LF. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
4. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
5. Pacher P, Szabo C. Role of the peroxynitrite-Poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 2008;173:2-13.
6. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002;59:1534-1553.
7. Hottiger MO, Boothby M, Koch-Nolte F, Luscher B, Martin NM, Plummer R, et al. Progress in the function and regulation of ADP-ribosylation. Sci Signal 2011;4:mr5.
8. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-440.
9. Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011;13:461-468.
10. Bai P, Canto C, Brunyanszki A, Huber A, Szanto M, Cen Y, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 2011;13:450-460.
11. Erener S, Mirsaidi A, Hesse M, Tiaden AN, Ellingsgaard H, Kostadinova R, et al. ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation. FASEB J 2012;26:2631-2638.
12. Erener S, Hesse M, Kostadinova R, Hottiger MO. Poly(ADP-ribose)polymerase-1 (PARP1) controls adipogenic gene expression and adipocyte function. Mol Endocrinol 2012;26:79-86.
13. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013;154:430-441.
14. Okada H, Inoue T, Kikuta T, Kato N, Kanno Y, Hirosawa N, et al. Poly(ADP-ribose) polymerase-1 enhances transcription of the profibrotic CCN2 gene. J Am Soc Nephrol 2008;19:933-942.
15. Huang D, Wang Y, Wang L, Zhang F, Deng S, Wang R, et al. Poly(ADP-ribose) polymerase 1 is indispensable for transforming growth factor-β induced Smad3 activation in vascular smooth muscle cell. PLoS ONE 2011;6:e27123.
16. Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774-1788.
17. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-344.
18. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-548.
19. Gao B, Jeong W-I, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008;47:729-736.
20. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-456.
21. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 1989;84:1786-1793.
22. Kinnman N, Goria O, Wendum D, Gendron M-C, Rey C, Poupon R, et al. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001;81:1709-1716.
23. Tong Z, Chen R, Alt DS, Kemper S, Perbal B, Brigstock DR. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 2009;50:939-947.
24. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor β Smad signal in hepatic fibrogenesis. Gut 2007;56:284-292.
25. Zhan S-S, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006;43:435-443.
26. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013 [Epub ahead of print].
27. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, Szabo C. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 2002;135:1347-1350.
28. Pacher P, Vaslin A, Benko R, Mabley JG, Liaudet L, Hasko G, et al. A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther 2004;311:485-491.